This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Khurana, S. Articles by Ben-Jonathan, N. Search for Related Content PubMed PubMed Citation Articles by Khurana, S. Articles by Ben-Jonathan, N. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Blood Thinners Hazardous Substances DB HEPARIN

Heparin-Binding Property of Human Prolactin: A Novel Aspect of Prolactin Biology

Department of Cell Biology, University of Cincinnati Medical School, Cincinnati, Ohio 45267

Address all correspondence and requests for reprints to: Nira Ben-Jonathan, Ph.D., University of Cincinnati, Department of Anatomy and Cell Biology, 231 Bethesda Avenue (ML 521), Cincinnati, Ohio 45267.

Prolactin (PRL) shares several characteristics with growth factors and cytokines, many of which are known to bind to heparan sulfate proteoglycans. In this study we examined the heparin-binding properties of selected members of the PRL/GH family, using heparin affinity columns followed by gel electrophoresis/Western blotting. Purified human PRL and its cleaved 16K fragment, but not human GH or placental lactogen, were retained on the heparin column and were displaced by 0.5 M NaCl. Native PRL in human pituitary extracts and amniotic fluid showed a similar binding affinity to heparin as the purified hormone. None of the other hormones tested, e.g., rat, ovine and bovine PRL, glycosylated ovine PRL or rat GH, bound to heparin. Two consensus heparin-binding sequences are present in human PRL but not in the other hormones included in this study. We postulate that the heparin-binding capability of PRL affects its biological activity as a growth factor and the angiostatic actions of its 16K fragment.

This article has been cited by other articles:

				E. R. Hugo, D. C. Borcherding, K. S. Gersin, J. Loftus, and N. Ben-Jonathan Prolactin Release by Adipose Explants, Primary Adipocytes, and LS14 Adipocytes J. Clin. Endocrinol. Metab., October 1, 2008; 93(10): 4006 - 4012. [Abstract] [Full Text] [PDF]

				S. M. K. Alam, T. Konno, N. Sahgal, L. Lu, and M. J. Soares Decidual Cells Produce a Heparin-binding Prolactin Family Cytokine with Putative Intrauterine Regulatory Actions J. Biol. Chem., July 4, 2008; 283(27): 18957 - 18968. [Abstract] [Full Text] [PDF]

				N. Ben-Jonathan, C. R. LaPensee, and E. W. LaPensee What Can We Learn from Rodents about Prolactin in Humans? Endocr. Rev., February 1, 2008; 29(1): 1 - 41. [Abstract] [Full Text] [PDF]

				S. M. K. Alam, T. Konno, G. Dai, L. Lu, D. Wang, J. H. Dunmore, A. R. Godwin, and M. J. Soares A uterine decidual cell cytokine ensures pregnancy-dependent adaptations to a physiological stressor Development, January 15, 2007; 134(2): 407 - 415. [Abstract] [Full Text] [PDF]

				Y. Macotela, M. B. Aguilar, J. Guzman-Morales, J. C. Rivera, C. Zermeno, F. Lopez-Barrera, G. Nava, C. Lavalle, G. M. de la Escalera, and C. Clapp Matrix metalloproteases from chondrocytes generate an antiangiogenic 16 kDa prolactin J. Cell Sci., May 1, 2006; 119(9): 1790 - 1800. [Abstract] [Full Text] [PDF]

				E. Ueda, U. Ozerdem, Y.-H. Chen, M. Yao, K. T. Huang, H. Sun, M. Martins-Green, P. Bartolini, and A. M Walker A molecular mimic demonstrates that phosphorylated human prolactin is a potent anti-angiogenic hormone. Endocr. Relat. Cancer, March 1, 2006; 13(1): 95 - 111. [Abstract] [Full Text] [PDF]

				E. R. Hugo, T. D. Brandebourg, C. E. S. Comstock, K. S. Gersin, J. J. Sussman, and N. Ben-Jonathan LS14: A Novel Human Adipocyte Cell Line that Produces Prolactin Endocrinology, January 1, 2006; 147(1): 306 - 313. [Abstract] [Full Text] [PDF]

				M. Zinger, M. McFarland, and N. Ben-Jonathan Prolactin Expression and Secretion by Human Breast Glandular and Adipose Tissue Explants J. Clin. Endocrinol. Metab., February 1, 2003; 88(2): 689 - 696. [Abstract] [Full Text] [PDF]

				S. Khurana, K. Liby, A. R. Buckley, and N. Ben-Jonathan Proteolysis of Human Prolactin: Resistance to Cathepsin D and Formation of a Nonangiostatic, C-Terminal 16K Fragment by Thrombin Endocrinology, September 1, 1999; 140(9): 4127 - 4132. [Abstract] [Full Text]